The Role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 4, 2011, Pages 193-202

  Alp, Ebru ^a   Menevse, Sevda ^a   Tulmac, Murat ^b   Yilmaz, Akin ^a   Yalcin, Ridvan ^a   Cengel, Atiye ^a  

^a GAZI UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CAD PROTEIN; GELATINASE A; GENOMIC DNA;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA ISOLATION; FEMALE; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; TURKEY;

EID: 79953069202     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2010.0113     Document Type: Article

References (48)

1. Abilleira S, Bevan S, Markus HS (2006) The role of genetic variants of matrix met al.loproteinases in coronary and carotid atherosclerosis. J Med Genet 43:897-901. (Pubitemid 46080185)
2. Alp E, Menevse S, Tulmac M, et al. (2009) Lack of association between matrix met al.loproteinase-9 and endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in Turkish population. DNA Cell Biol 28:343-350.
3. Armstrong C, Abilleira S, Sitzer M, et al. (2007) Polymorphisms in MMP family and TIMP genes and carotid artery intimamedia thickness. Stroke 38:2895-2899. (Pubitemid 350035681)
4. Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, et al. (2008) Polymorphism in the matrix met al.loproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet 46:137-144.
5. Barrett JC, Fry B, Maller J, et al. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. (Pubitemid 40202029)
6. Bauters C, Lamblin N, Ennezat PV, et al. (2007) A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and met al.loproteinase systems. Am Heart J 153:641-648. (Pubitemid 46440689)
7. Beránek M, Kolar P, Tschoplova S, et al. (2008) Genetic variations and plasma levels of gelatinase A (matrix met al.loproteinase-2) and gelatinase B (matrix met al.loproteinase-9) in proliferative diabetic retinopathy. Mol Vis 14:1114-1121. (Pubitemid 351850566)
8. Cam SF, Sekuri C, Tengiz I, et al. (2005) The G894T polymorphism on endothelial nitric oxide synthase gene is associated with premature coronary artery disease in a Turkish population. Thromb Res 116:287-292. (Pubitemid 40994910)
9. Cotignola J, Roy P, Patel A, et al. (2007) Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. J Negat Results Biomed 24:6-9.
10. Delgado-Enciso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. (2008) Matrix met al.loproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Invest 65:68-72.
11. Excoffier L, Laval G, Schneider S (2005) Arlequin ver. 3.0. An integrated software package for population genetics data analysis. Evol Bioinform Online 1:47-50.
12. Excoffier L, Slatkin M (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921-927.
13. Fatar M, Stroick M, Steffens M, et al. (2008) Single-nucleotide polymorphisms of MMP-2 gene in stroke subtypes. Cerebrovasc Dis 26:113-119.
14. Galis ZS, Sukhova GK, Lark MW, et al. (1994) Increased expression of matrix met al.loproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503. (Pubitemid 24379627)
15. Gremlich S, Nguyen D, Reymondin D, et al. (2007) Fetal MMP2/MMP9 polymorphisms and intrauterine growth restriction risk. J Reprod Immunol 74:143-151. (Pubitemid 46679071)
16. Gürkan A, Emingil G, Saygan BH, et al. (2008) Gene polymorphisms of matrix met al.loproteinase-2,-9 and-12 in periodontal health and severe chronic periodontitis. Arch Oral Biol 53:337-345.
17. Harendza S, Lovett DH, Panzer U, et al. (2003) Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 278:20490-20499. (Pubitemid 36806345)
18. Hinterseher I, Bergert H, Kuhlisch E, et al. (2006) Matrix metalloproteinase 2 polymorphisms in a caucasian population with abdominal aortic aneurysm. J Surg Res 133:121-128. (Pubitemid 43765757)
19. Hlatky MA, Ashley E, Quertermous T, et al. (2007) Matrix met al.loproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 154:1043-1051. (Pubitemid 350116029)
20. Hojo Y, Ikeda U, Ueno S, et al. (2001) Expression of matrix met al.loproteinases in patients with acute myocardial infarction. Jap Circ J 65:71-75.
21. Holla LI, Fassmann A, Vasku A, et al. (2005) Genetic variations in the human gelatinase A (matrix met al.loproteinase-2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis. J Periodontol 76:1056-1060. (Pubitemid 41065393)
22. Horne BD, Camp NJ, Carlquist JF, et al. (2007) Multiplepolymorphism associations of 7 matrix met al.loproteinase and tissue inhibitor met al.loproteinase genes with myocardial infarction and angiographic coronary artery disease. Am Heart J 154:751-758. (Pubitemid 47429598)
23. Hua Y, Song L, Wu N, et al. (2009) Polymorphisms of MMP-2 gene are associated with systolic heart failure risk in Han Chinese. Am J Med Sci 337:344-348.
24. Jaramillo PC, Munoz MA, Lanas MC, et al. (2006) Endothelial nitric oxide synthase G894T gene polymorphism in Chilean subjects with coronary artery disease and controls. Clin Chim Acta 371:102-106. (Pubitemid 44177579)
25. Kai H, Ikeda H, Yasukawa H, et al. (1998) Peripheral blood levels of matrix met al.loproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368-372. (Pubitemid 28396484)
26. Kim IJ, Bae J, Lim SW, et al. (2007) Influence of endothelial nitric oxide synthase gene polymorphisms (786T/C, 4a4b, 894G/T) in Korean patients with coronary artery disease. Thromb Res 119:579-585.
27. Lamblin N, Bauters C, Hermant X, et al. (2002) Polymorphisms inthe promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40:43-48. (Pubitemid 34701375)
28. Lei H, Hemminki K, Altieri A, et al. (2007) Promoter polymorphisms in matrix met al.loproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat 103:61-69. (Pubitemid 46653260)
29. Libby P (2000) Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol 86 (Suppl): 3J-9J.
30. Lin TH, Chiu HC, Lee YT, et al. (2007) The C-allele of tissue inhibitor of met al.loproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese-4-year follow-up study. Clin Chim Acta 386:87-93.
31. Matyar S, Attila G, Acartürk E, et al. (2005) eNOS gene intron 4 a/b VNTR polymorphism is a risk factor for coronary artery disease in Southern Turkey. Clin Chim Acta 354:153-158. (Pubitemid 40320686)
32. Nielsen DM, Ehm MG, Weir BS. (1998) Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. Am J Hum Genet 63:1531-1540. (Pubitemid 30418550)
33. Nilsson L, Jonasson L, Nijm J, et al. (2006) Increased plasma concentration of matrix met al.loproteinase-7 in patients with coronary artery disease. Clin Chem 52:1522-1527. (Pubitemid 44148315)
34. Orbe J, Fernandez L, Rodríguez JA, et al. (2003) Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis 170:269-276. (Pubitemid 37377799)
35. Pollanen PJ, Karhunen PJ, Mikkelsson J, et al. (2001) Coronary artery complicated lesion area is related to functional polymorphism of matrix met al.loproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 21:1446-1450. (Pubitemid 34219806)
36. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix met al.loproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549-7558.
37. Qin H, Sun Y, Benveniste en (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix met al.loproteinase-2 gene expression in astroglioma cells. J Biol Chem 274:29130-29137.
38. Sole X, Guino E, Valls J, et al. (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:928-1929.
39. Tsakiris DA, Battegay E, Heilmbauer I, et al. (2004) Inverse regulation of MMP-9 and MMP-2 in long-term follow-up after acute coronary syndrome: lack of correlation with platelet and endothelial cell activation markers. Vasc Dis Prev 1:149-157.
40. Tyagi SC, Kumar SG, Haas SJ, et al. (1996) Post-transcriptional regulationof extracellular matrix met al.loproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28:1415-1428. (Pubitemid 26340896)
41. Vasků A, Goldbergová M, Hollá LI, et al. (2003) Two MMP-2 promoter polymorphisms (-790T/G and-735C/T) in chronic heart failure. Clin Chem Lab Med 41:1299-1303.
42. Vasků A, Goldbergová M, Izakovicová Hollá L, et al. (2004) A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A,-1306C/T,-790T/G and-735C/T) is associated with coronary triple-vessel disease. Matrix Biol 22:585-591. (Pubitemid 38283782)
43. Vasku V, Bienertova Vasku J, Slonková V, et al. (2009) Matrix met al.loproteinase-2 promoter variability in psoriasis. Arch Dermatol Res 301:467-473.
44. Xu E, Xia X, Lü B, et al. (2007) Association of matrix met al.loproteinase-2 and-9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog 46:924-929. (Pubitemid 350058412)
45. Yu C, Zhou Y, Miao X, et al. (2004) Functional haplotypes in the promoter of matrix met al.loproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622-7628. (Pubitemid 39372109)
46. Zeng B, Prasan A, Fung KC, et al. (2005) Elevated circulating levels of matrix met al.loproteinase-9 and-2 in patients with symptomatic coronary artery disease. Intern Med J 35:331-335. (Pubitemid 40826856)
47. Zhou G, Zhai Y, Cui Y, et al. (2007) Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat 28:1091-1097. (Pubitemid 350036913)
48. Zhou Y, Yu C, Miao X, et al. (2005) Functional haplotypes in the promoter of matrix met al.loproteinase-2 and lung cancer susceptibility. Carcinogenesis 26:1117-1121. (Pubitemid 41214305)